A Randomized, Double-blinded, Single-centre, Parallel-group, Placebo-controlled, Prospective Trial of Neuroprotective Effect of Liraglutide for Treatment of Diabetic Neuropathy.
Phase of Trial: Phase II
Latest Information Update: 10 May 2019
Price : $35 *
At a glance
- Drugs Liraglutide (Primary)
- Indications Diabetic neuropathies; Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms TODINELI
- 05 Oct 2018 Results presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
- 31 Aug 2018 Biomarkers information updated
- 02 Mar 2017 Status changed from recruiting to completed.